COVID‐19: A Catalyst to Accelerate Global Regulatory Transformation
STEWART et al.

A global crisis the magnitude of coronavirus disease 2019 (COVID‐19) can transform drug development and review. It has exposed vulnerabilities and inadequacies in the global healthcare ecosystem as well as s